New CAR T strategy highly effective against small cell lung cancer in preclinical study

Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

Pasi A. Jänne received the GO2 for Lung Cancer’s 2024 Bonnie J. Addario Lectureship Award.

August 02, 2024

Vaping and smoking together increases lung cancer risk fourfold

People who both vape and smoke are four times more likely to develop lung cancer than people who just smoke, according to a new study published by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and College of Public Health.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Ninety-three percent of oncologists adjust treatment recommendations with OncoHost’s PROphetNSCLC test

OncoHost, a technology company, announced the publication of a study in Clinical Lung Cancer demonstrating the impact of its PROphetNSCLC test on first-line treatment decisions for metastatic non-small cell lung cancer patients.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Neighborhood violence may influence tumor biology, worsening lung cancer outcomes

Scientists have identified a potential driver of aggressive lung cancer tumors in patients who live in areas with high levels of violent crime. Their study found that stress responses differ between those living in neighborhoods with higher and lower levels of violent crime, and between cancerous and healthy tissues in the same individuals.

July 26, 2024

Vol.50 No.30

Clinical Roundup

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

A new study details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the clinical-stage cell therapy company Vittoria Biotherapeutics’ proprietary Senza5TM platform.

July 26, 2024

Vol.50 No.30

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

July 12, 2024

Vol.50 No.28

By Matthew Bin Han Ong

New CAR T strategy highly effective against small cell lung cancer in preclinical study

YOU MAY BE INTERESTED IN

Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

Vaping and smoking together increases lung cancer risk fourfold

Ninety-three percent of oncologists adjust treatment recommendations with OncoHost’s PROphetNSCLC test

Neighborhood violence may influence tumor biology, worsening lung cancer outcomes

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

Renew today!

Subscriber content

Login

New CAR T strategy highly effective against small cell lung cancer in preclinical study

YOU MAY BE INTERESTED IN

Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

Vaping and smoking together increases lung cancer risk fourfold

Ninety-three percent of oncologists adjust treatment recommendations with OncoHost’s PROphetNSCLC test

Neighborhood violence may influence tumor biology, worsening lung cancer outcomes

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Infections are a major cause of death in patients treated with CAR T-cell therapyMeta-analysis focused on causes of death, excluding relapse, recurrence

Login

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence